NRX Pharmaceuticals (NRXP) Other financing activities (2018 - 2025)
NRX Pharmaceuticals (NRXP) posted quarterly Other financing activities of $3.1 million for Q4 2025, up 61.88% year-over-year from $1.9 million in Q4 2024, and up 61.88% quarter-over-quarter from $1.9 million in Q4 2024.
NRX Pharmaceuticals (NRXP) Other financing activities (2018 - 2025) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Other financing activities for 6 consecutive years, with $3.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities rose 61.88% year-over-year to $3.1 million; the TTM figure through Dec 2025 stood at $3.1 million (down 22.16% YoY), while the FY2025 annual figure was $3.1 million, down 22.16% from the prior year.
- Other financing activities improved to $3.1 million in Q4 2025 per NRXP's latest filing, from $1.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $9.2 million in Q3 2021 and bottomed at -$5.6 million in Q4 2021.
- Historically, Other financing activities has averaged $2.7 million across 3 years, with a median of $2.5 million in 2024.
- Annual changes were most pronounced in 2021 — Other financing activities soared 600.84% — and 2025, when it surged 61.88%.
- NRX Pharmaceuticals' Other financing activities stood at -$5.6 million in 2021, then soared by 133.75% to $1.9 million in 2024, then soared by 61.88% to $3.1 million in 2025.
- Business Quant data shows NRXP's Other financing activities at $3.1 million in Q4 2025, $1.9 million in Q4 2024, and $1.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.09 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2021 | -5.65 Mn |
| Dec 31, 2021 | -5.65 Mn |
| Sep 30, 2021 | 9.20 Mn |
| Sep 30, 2021 | 9.20 Mn |
| Jun 30, 2021 | 3.55 Mn |
| Jun 30, 2021 | 3.55 Mn |
| Mar 31, 2021 | 7.50 Mn |
| Mar 31, 2021 | 7.50 Mn |
| Mar 31, 2020 | -1.50 Mn |
| Mar 31, 2020 | -1.50 Mn |
| Sep 30, 2019 | -147,988.00 |
| Sep 30, 2019 | -147,988.00 |